Commentary

Video

Dr Shields on Updates in Upfront Systemic Therapy in ES-SCLC

Misty D. Shields, MD, PhD, discusses systemic therapy updates for patients with extensive-stage small cell lung cancer.

Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, associate member, Experimental and Developmental Therapeutics, Indiana University School of Medicine, discusses systemic therapy updates for patients with extensive-stage small cell lung cancer (ES-SCLC).

At the 2023 IASLC World Conference on Lung Cancer, Dr Shields presented the latest updates in upfront systemic therapy for patients with ES-SCLC. One important study discussed at this meeting was the IMbrella A trial, Shields says. IMbrella A was an observational extension study of the phase 3 IMpower133 trial (NCT02763579), which evaluated atezolizumab (Tecentriq) or placebo plus carboplatin and etoposide in patients with treatment-naïve ES-SCLC. Patients from the atezolizumab arm of IMpower133 were eligible for enrollment in IMbrella A if they continued to receive atezolizumab after the study’s closure or were in survival follow-up after IMpower133 closed. At a median follow-up of 59.4 months (range, 0.0-72.6), the median OS in the atezolizumab arm of IMpower133 was 12.3 months (95% CI, 10.8-15.8). The median OS in the placebo arm of this study was 10.3 months (95% CI, 9.3-11.3) at a median follow-up of 26.4 months (range, 0.0-34.4).

Additionally, the combined 5-year OS rate in the IMpower133 and IMbrella A atezolizumab cohort was 12% (95% CI, 7%-17%).

Findings from the phase 3 ETER701 trial (NCT04234607) were also reported at the meeting. This trial evaluated the PD-L1 inhibitor benmelstobart (TQB2450) plus anlotinib (AL3818) and carboplatin/etoposide vs anlotinib plus placebo and carboplatin/etoposide vs placebo plus carboplatin/etoposide in patients with previously untreated ES-SCLC, Shields explains. In this trial, patients in the benmelstobart arm achieved a median OS of 19.32 months (95% CI, 14.23-not evaluable) vs 11.89 months (95% CI, 10.74-13.37) for those in the placebo plus carboplatin/etoposide arm. Additionally, the median progression-free survival was 6.93 months (95% CI, 6.18-8.25) in the benmelstobart arm vs 4.21 months (95% CI, 4.17-4.24) in the placebo plus carboplatin/etoposide arm.

Related Videos
Yungan Tao, MD
Jared Weiss, MD
Guru P. Sonpavde, MD
Martin H. Voss, MD
Sally Lau, MD
Hope S. Rugo, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Srikala Sridhar, MD, MSc, FRCPC